1. Home
  2. VSEC vs MLYS Comparison

VSEC vs MLYS Comparison

Compare VSEC & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VSEC
  • MLYS
  • Stock Information
  • Founded
  • VSEC 1959
  • MLYS 2019
  • Country
  • VSEC United States
  • MLYS United States
  • Employees
  • VSEC N/A
  • MLYS N/A
  • Industry
  • VSEC Military/Government/Technical
  • MLYS Biotechnology: Pharmaceutical Preparations
  • Sector
  • VSEC Consumer Discretionary
  • MLYS Health Care
  • Exchange
  • VSEC Nasdaq
  • MLYS Nasdaq
  • Market Cap
  • VSEC 3.4B
  • MLYS 3.1B
  • IPO Year
  • VSEC N/A
  • MLYS 2023
  • Fundamental
  • Price
  • VSEC $180.68
  • MLYS $40.86
  • Analyst Decision
  • VSEC Strong Buy
  • MLYS Strong Buy
  • Analyst Count
  • VSEC 5
  • MLYS 6
  • Target Price
  • VSEC $196.80
  • MLYS $44.60
  • AVG Volume (30 Days)
  • VSEC 263.6K
  • MLYS 1.1M
  • Earning Date
  • VSEC 10-27-2025
  • MLYS 11-12-2025
  • Dividend Yield
  • VSEC 0.22%
  • MLYS N/A
  • EPS Growth
  • VSEC N/A
  • MLYS N/A
  • EPS
  • VSEC 0.54
  • MLYS N/A
  • Revenue
  • VSEC $1,332,372,000.00
  • MLYS N/A
  • Revenue This Year
  • VSEC $2.95
  • MLYS N/A
  • Revenue Next Year
  • VSEC $13.76
  • MLYS N/A
  • P/E Ratio
  • VSEC $63.53
  • MLYS N/A
  • Revenue Growth
  • VSEC 67.77
  • MLYS N/A
  • 52 Week Low
  • VSEC $88.69
  • MLYS $8.24
  • 52 Week High
  • VSEC $186.00
  • MLYS $44.80
  • Technical
  • Relative Strength Index (RSI)
  • VSEC 64.76
  • MLYS 56.81
  • Support Level
  • VSEC $176.52
  • MLYS $39.44
  • Resistance Level
  • VSEC $185.35
  • MLYS $43.43
  • Average True Range (ATR)
  • VSEC 6.34
  • MLYS 2.04
  • MACD
  • VSEC 1.71
  • MLYS -0.79
  • Stochastic Oscillator
  • VSEC 82.54
  • MLYS 27.97

About VSEC VSE Corporation

VSE Corp is a diversified aftermarket products and services company providing repair services, parts distribution, logistics, supply chain management, and consulting services for land, sea, and air transportation assets to commercial and government markets. Its operations include supply chain management solutions, parts supply and distribution, and maintenance, repair, and overhaul (MRO) services for vehicle fleet, aviation, maritime and other customers. Its reportable segments are; Aviation and Fleet. The majority of the revenue for the company is generated from the Aviation segment which is a provider of aftermarket parts distribution and MRO services for components and engine accessories supporting commercial, business, and general aviation operators.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: